期刊文献+

血清CA125检测在肝硬化患者肝功能损害评价中的临床意义 被引量:5

暂未订购
导出
摘要 目的探讨血清癌抗原125(CA125)和肝硬化患者肝功能损害的关系。方法选择宿迁市东方医院2011年1月-2012年12月收治的100例肝硬化患者,其中男74例,女26例,年龄28~65岁,平均(45±7.8)岁,均为乙型肝炎后出现肝硬化,根据Child-Pugh分级标准,A级为42例,B级38例,C级20例;另将同期在该院行健康体检者50例作为正常对照组,男26例,女24例,年龄25~62岁,平均平均(43±6.5)岁。通过ELISA法来测定血清中CA125浓度,分析其与肝功能分级的关系。结果肝硬化患者血清CA125浓度与对照组相比,差异有统计学意义(P〈0.01)。且血清CA125浓度与肝功能损害程度呈正相关。结论血清CA125是反映肝硬化患者肝功能损害程度的指标之一,CA125浓度可用于判断肝硬化患者肝功能损害程度及预后。
作者 潘晴
出处 《中国医学工程》 2013年第12期145-145,147,共2页 China Medical Engineering
  • 相关文献

参考文献5

  • 1Kalantri Y,Naik G,Joshi SP,et al.Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions[J].Indian J Med Res,2007,125(1):25-30.
  • 2石仁芳,陈晓燕.血清CA125水平变化在肝硬化患者中的临床意义[J].华夏医学,2006,19(6):1121-1122. 被引量:1
  • 3Kemer T,Ormen M,Kuralay F,et al.Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions[J].Tohoku J Exp Med,2005,205(1):l 1-18.
  • 4Kalambokis G,Kostoula A,Economou M,et al.Tumor necrosis factor- alpha-related intraperitoneal release of CA 125 in cirrhotic patients with sterile ascites[J].Clin Chem,2005,51(11):2207-2208.
  • 5Leggio L,Abenavoli L,D'Angelo C,et al.Marked decrease of serum Ca 125 levels after Denver shunt placement in a patient with cirrhosis and refractory ascites[J].Dig Dis Sci,2006,51 (9): 1644-1646.

二级参考文献5

同被引文献53

  • 1Raja GR Edula,Sujit Muthukuru,Serban Moroianu,Yucai Wang,Vivek Lingiah,Phoenix Fung,Nikolaos T Pyrsopoulos.CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study[J].Journal of Clinical and Translational Hepatology,2018,6(3):241-246. 被引量:7
  • 2高小萌,商建利,周彰.肝癌并门脉高压门脉内有、无癌栓病例临床影像对照分析[J].江西医药,2005,40(10):598-600. 被引量:1
  • 3中华医学会肝病学会,中华医学会感染病学会.慢性乙型肝炎防治指南(2010年版)[J].中华肝胆病杂志(电子版),2011,3(1):40-55.
  • 4Epiney M,Bertossa C,Weil A,et al. CA125 production by the preitioneum: in-vitro and in-vivo studies [J]. humans reproduction, 2000,15 : 1261-1265.
  • 5Colloca G, Venturino A, Assano G, et al. CA125-related measures of tumor kinetics and outcome of patiens with recurrent ovarian cancer receiving chemotherapy., a retro- spective evaluation [J]. Jap J Clin Oncol, 2013,43 (12) .. 1203-1209.
  • 6Schoniger-Hekele M, Maller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease pa- tients is highly specific for severe liver fibrosis[J]. Dig Dis Sci,2006,51(2) :338-345.
  • 7Bast R C Jr, Feeney M, Lazarus H,et al. Reativity of a monclonedantibody with human ovarian cancer. J Clin Invest, 1981,68(5):1331-1337.
  • 8Colloca G, Venturino A, Addamo G,et al. CA125-related measuresof tumor kinetics and outcome ofpatiens with recurreat ovariancancer receiving chemotherapy : a retrospective Evaluation. Jpn JClin Oncol,2013,43(12) : 1202-1209.
  • 9谢万昌,章菲菲.肝硬化患者检测血清CA125的临床意义[J].临床军医杂志,2008,36(2):227-228. 被引量:4
  • 10何芳,王明友,杨少奇,杨力.血清CA125浓度与腹水复发关系的探讨[J].宁夏医学杂志,2008,30(5):433-434. 被引量:2

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部